Biologically Active Small Molecules

A potent, allosteric inhibitor of Akt1 and Akt2 (IC₅₀ = 58 and 210 nM, respectively) that less effectively blocks Akt3 activity (IC₅₀ = 2.2 &microM) cell permeable, blocking insulin regulation of FOXO1 activity at 1 &microM

A cell permeable phenoxazine derivative that suppresses IGF-1-stimulated phosphorylation of Akt with an IC₅₀ value of 1-2 &muM inhibits the growth of Rh1, Rh18, and Rh30 cells with IC₅₀ values of 2-5 &muM.

A cell permeable phenoxazine derivative that suppresses IGF-1-stimulated phosphorylation of Akt with an IC₅₀ value of 1-2 &muM inhibits the growth of Rh1, Rh18, and Rh30 cells with IC₅₀ values of 2-5 &muM.

A cell permeable phenoxazine derivative that suppresses IGF-1-stimulated phosphorylation of Akt with an IC₅₀ value of 1-2 &muM inhibits the growth of Rh1, Rh18, and Rh30 cells with IC₅₀ values of 2-5 &muM.

A cell permeable phenoxazine derivative that suppresses IGF-1-stimulated phosphorylation of Akt with an IC₅₀ value of 1-2 &muM inhibits the growth of Rh1, Rh18, and Rh30 cells with IC₅₀ values of 2-5 &muM.

A cell-permeable, copper-containing 3-formylchromone derivative that inhibits Akt in an array of cancer cells (IC₅₀s = 10-34 &microM) also causes NF-&kappaB inactivation in an orthotopic pancreatic tumor model using COLO 357 cells.

A cell-permeable, copper-containing 3-formylchromone derivative that inhibits Akt in an array of cancer cells (IC₅₀s = 10-34 &microM) also causes NF-&kappaB inactivation in an orthotopic pancreatic tumor model using COLO 357 cells.

A cell-permeable, copper-containing 3-formylchromone derivative that inhibits Akt in an array of cancer cells (IC₅₀s = 10-34 &microM) also causes NF-&kappaB inactivation in an orthotopic pancreatic tumor model using COLO 357 cells.

A cell-permeable, copper-containing 3-formylchromone derivative that inhibits Akt in an array of cancer cells (IC₅₀s = 10-34 &microM) also causes NF-&kappaB inactivation in an orthotopic pancreatic tumor model using COLO 357 cells.

A potent 5-HT2 receptor agonist with ocular hypotensive activity binds to the human and rat 5-HT2 receptors in cerebral cortex homogenates with IC50 values of 1.5 and 0.

A potent 5-HT2 receptor agonist with ocular hypotensive activity binds to the human and rat 5-HT2 receptors in cerebral cortex homogenates with IC50 values of 1.5 and 0.

A potent 5-HT2 receptor agonist with ocular hypotensive activity binds to the human and rat 5-HT2 receptors in cerebral cortex homogenates with IC50 values of 1.5 and 0.